

September 3, 2024

General Announcement:

Senju Pharmaceutical Co., Ltd.

Acquisition of Marketing Approval for “ Mytear LUMIFY”

Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received approval for the marketing of “Mytear Lumify” (OTC drug requiring instruction by pharmacist, hereinafter this "Product") from Ministry of Health, Labour and Welfare.

This Product is the first eye drop in Japan containing “Brimonidine tartrate”, an ingredient that relieves hyperemia and is effective for Conjunctival hyperemia.

The release date and product specifications will be announced at a later date.

Overview of the Product

| Product name | Mytear LUMIFY | | | | | | | | |
|---|---|----------------------------|------------|-----|--------|------------|--------------------------------------|--------|----------------------------|
| Category | OTC drug requiring instruction by pharmacist | | | | | | | | |
| Indications | Conjunctival hyperemia | | | | | | | | |
| Dosage and administration | <table border="1"> <thead> <tr> <th>Age</th> <th>Dosage</th> <th>Daily dose</th> </tr> </thead> <tbody> <tr> <td>Adults (15 years of age and over)</td> <td>1 drop</td> <td>No more than 4 times daily</td> </tr> </tbody> </table> | | | Age | Dosage | Daily dose | Adults (15 years of age and over) | 1 drop | No more than 4 times daily |
| | Age | Dosage | Daily dose | | | | | | |
| Adults (15 years of age and over) | 1 drop | No more than 4 times daily | | | | | | | |
| Instill eye drops at least 4 hours apart. | | | | | | | | | |
| Active ingredient | Brimonidine tartrate ...0.1 mg / 1 mL | | | | | | | | |

[Contact details for inquiries]

| |
|---|
| <p>Corporate Communication Department, Senju Pharmaceutical Co., Ltd. 3-1-9, Kawara-machi, Chuo-ku, Osaka 541-0048, Japan Mail: cc@senju.co.jp URL: https://www.senju.co.jp</p> |
|---|